|
Leukemia, Myelocytic, Acute
|
0.320 |
Biomarker
|
disease |
BEFREE |
Surprisingly however, NHD13 transgenic mice lacking Lyl1 showed accelerated T-ALL and absence of transformation to AML, associated with a loss of multipotent progenitors in the bone marrow.
|
30700838 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.320 |
Biomarker
|
disease |
CTD_human |
These results demonstrate that LYL1 may play a role in early hematopoiesis and may be a potential oncogenic factor in AML.
|
16094422 |
2005 |
|
Leukemia, Myelocytic, Acute
|
0.320 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that LYL1 may play a role in early hematopoiesis and may be a potential oncogenic factor in AML.
|
16094422 |
2005 |
|
Lymphoid leukemia
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
We postulated that functional redundancy with its closely related family member, lymphoblastic leukemia 1 (Lyl1) might explain this observation.
|
31300405 |
2019 |
|
MYELODYSPLASTIC SYNDROME
|
0.310 |
Biomarker
|
group |
CTD_human |
Using real-time quantitative RT-PCR assay, we found that the expression of LYL1 was at higher levels in the majority cases of acute myeloblastic leukemia (AML) or myelodysplastic syndrome when compared to normal bone marrow.
|
16094422 |
2005 |
|
MYELODYSPLASTIC SYNDROME
|
0.310 |
AlteredExpression
|
group |
BEFREE |
Using real-time quantitative RT-PCR assay, we found that the expression of LYL1 was at higher levels in the majority cases of acute myeloblastic leukemia (AML) or myelodysplastic syndrome when compared to normal bone marrow.
|
16094422 |
2005 |
|
Lymphoid leukemia
|
0.310 |
Biomarker
|
disease |
CTD_human |
Chromosomal translocation involving the beta T cell receptor gene in acute leukemia.
|
3162254 |
1988 |
|
Acute Myeloid Leukemia, M1
|
0.300 |
Biomarker
|
disease |
CTD_human |
Oncogenic potential of the transcription factor LYL1 in acute myeloblastic leukemia.
|
16094422 |
2005 |
|
Acute Myeloid Leukemia (AML-M2)
|
0.300 |
Biomarker
|
disease |
CTD_human |
Oncogenic potential of the transcription factor LYL1 in acute myeloblastic leukemia.
|
16094422 |
2005 |
|
Hematopoetic Myelodysplasia
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Oncogenic potential of the transcription factor LYL1 in acute myeloblastic leukemia.
|
16094422 |
2005 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Surprisingly however, NHD13 transgenic mice lacking Lyl1 showed accelerated T-ALL and absence of transformation to AML, associated with a loss of multipotent progenitors in the bone marrow.
|
30700838 |
2019 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data provide insight into the mechanisms controlling lymphocyte specification and may reveal a basis for the unique functions of Tal1 and Lyl1 in T acute lymphoblastic leukemia.
|
30962294 |
2019 |
|
Intelligence
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Large-Scale Cognitive GWAS Meta-Analysis Reveals Tissue-Specific Neural Expression and Potential Nootropic Drug Targets.
|
29186694 |
2017 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the LMO2-LYL1 interaction is a promising therapeutic target for inhibiting self-renewing cancer stem cells in T-ALL, including poor-prognosis ETP-ALL cases.
|
23926305 |
2013 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In hematopoiesis, the two major bHLH factors are stem cell leukemia (SCL) and lymphoblastic leukemia-derived sequence 1 (LYL1), both identified more than 20 years ago in chromosomal translocations occurring in T-cell acute lymphoblastic leukemia.
|
22593015 |
2012 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Molecular characterization of a t(7;19)(q34;p13) in a pediatric T-cell acute lymphoblastic leukemia patient led to the identification of a translocation between the TRB@ and LYL1 loci.
|
22058201 |
2012 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TAL1, LYL1, HOX11 and other transcription factors essential for normal hematopoiesis are often misexpressed in the thymus in T-cell acute lymphoblastic leukemia (T-ALL), leading to differentiation arrest and cell transformation.
|
17934490 |
2007 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
LYL1, a member of the class II basic helix-loop-helix transcription factors, is aberrantly expressed in a fraction of human T-cell acute lymphoblastic leukemia.
|
17486074 |
2007 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The LYL1 gene encodes a basic helix-loop-helix transcription factor involved in T-cell acute lymphoblastic leukemia.
|
16094422 |
2005 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TAL2 potentially encodes a basic helix-loop-helix motif that is highly related to those specified by TAL1 and LYL1, distinct genes that have also been implicated in T-ALL.
|
8152805 |
1994 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The bHLH domain of TAL1 is especially homologous to those encoded by TAL2 and LYL1, distinct genes that were also identified on the basis of chromosomal rearrangement in T-ALL.
|
8142619 |
1993 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hence, TAL2, TAL1, and LYL1 constitute a discrete subgroup of helix-loop-helix proteins, each of which can potentially contribute to the development of T-ALL.
|
1763056 |
1991 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The E2A gene is involved by the t(1;19)(q23;p13) in acute pre-B-cell leukemias and the LYL1 gene is structurally altered by a t(7;19)(q34;p13) in T-cell ALL.
|
2268576 |
1990 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
However, multivariate analyses adjusted for tumor histologic type, grade, and stage did not confirm LYL1 gene amplification as an independent prognostic factor for either PFS or OS.
|
29716549 |
2018 |
|
leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
By contrast, TAL1, another suspected oncoprotein in leukemia and close relative of LYL1, exerts no regulatory effect on the STMN1 promoter.
|
23000483 |
2013 |